Parkinson's Disease Levodopa-Induced Dyskinesia Market: Epidemiology, Therapies, and Key Companies Working, DelveInsight | PharmaTher Inc., Neurolixis SAS, Gala laboratories, Bukwang Pharmaceutical, Contera Pharma, Vistagen, Ipsen Pharma, Newron Pharmaceu

Parkinson's Disease Levodopa-Induced Dyskinesia emerging therapies, such as GOCOVRI, JM-010, and NLX-112, are expected to boost the Parkinson's Disease Levodopa-Induced Dyskinesia Market in the upcoming years.

DelveInsight has launched a new report on "Parkinson's Disease Levodopa-Induced Dyskinesia - Market Insights, Epidemiology, and Market Forecast-2034" that delivers an in-depth understanding of the Parkinson's Disease Levodopa-Induced Dyskinesia, historical and forecasted epidemiology as well as the Parkinson's Disease Levodopa-Induced Dyskinesia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Request for a detailed sample report @ https://www.delveinsight.com/report-store/parkinsons-disease-levodopa-induced-dyskinesia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Recent advancements in the Parkinson's Disease Levodopa-Induced Dyskinesia Market:
In March 2025, MedRhythms announced that MR-005, its neurorehabilitation system designed to support gait rehabilitation and motor function in adults with Parkinson's disease, has been classified as a Class II, Rx-only medical device by the FDA. The system will be marketed under the brand name Movive.
In February 2025, Medtronic received FDA approval for its BrainSenseTM Adaptive Deep Brain Stimulation (aDBS) for Parkinson's disease, marking a significant advancement in neuromodulation therapy.
In February 2025, Supernus Pharmaceuticals, Inc. announced that the U.S. FDA approved ONAPGO (apomorphine hydrochloride) injection, formerly known as SPN-830, as the first and only subcutaneous apomorphine infusion device for treating motor fluctuations in adults with advanced Parkinson's disease.
In October 2024, AbbVie announced that it has received FDA approval for VYALEV (foscarbidopa/foslevodopa), a treatment for motor fluctuations in adults with advanced Parkinson's disease. This marks the first 24-hour continuous subcutaneous infusion of a levodopa-based therapy.

Some of the key facts of the Parkinson's Disease Levodopa-Induced Dyskinesia Market Report:

In 2023, the total market size for Parkinson's Disease Levodopa-induced Dyskinesia treatment in the US was around USD 900 billion.
In 2021, Supernus Pharmaceuticals' GOCOVRI received FDA approval for the treatment of OFF episodes in Parkinson's disease patients who are on levodopa therapy and also experience dyskinesia and other motor complications. Despite its benefits, GOCOVRI has been associated with side effects such as hallucinations, dizziness, dry mouth, peripheral swelling, constipation, falls, and orthostatic hypotension.
Although various medications and treatment strategies exist for managing Parkinson's Disease Levodopa-Induced Dyskinesia (PD-LID), none are universally effective. The limited effectiveness of current therapies underscores the need for continued research and innovation to develop more targeted treatments for dyskinesia.
Additionally, patient responses to levodopa and the onset of dyskinesias can vary significantly. Some individuals may develop dyskinesia early in their treatment journey, while others only after several years, making it difficult to predict and manage these symptoms consistently.
Encouragingly, a number of pharmaceutical companies are actively developing novel therapies for PD-LID, including NLX-112 (Neurolixis SAS/Gala Laboratories), JM-010 (Bukwang Pharmaceutical/Contera Pharma), KETARX (ketamine) by PharmaTher, and AV-101 from Vistagen. These emerging treatments are expected to positively impact the PD-LID market during the forecast period from 2024 to 2034.
In 2023, Germany had the highest number of patients developing Parkinson's disease Levodopa-induced Dyskinesia among the EU4 and the UK, with around 67 thousand cases, followed by France with approximately 56 thousand and Italy with around 47 thousand. In the US, approximately 240 thousand individuals were affected by Parkinson's disease Levodopa-induced Dyskinesia, with 88 thousand experiencing off-period dystonia, 59 thousand with diphasic dyskinesia, and the remainder dealing with peak-dose dyskinesia. These numbers are expected to shift by 2034 due to the aging population, which is anticipated to see a rise in Parkinson's disease Levodopa-induced Dyskinesia cases.
Key Parkinson's Disease Levodopa-Induced Dyskinesia companies such as PharmaTher Inc., Neurolixis SAS, Gala laboratories, Bukwang Pharmaceutical, Contera Pharma, Vistagen, Ipsen Pharma, Newron Pharmaceuticals, Zambon Pharmaceuticals, Celon Pharma SA, and others are evaluating new drugs for Parkinson's Disease Levodopa-Induced Dyskinesia to improve the treatment landscape.
Promising Parkinson's Disease Levodopa-Induced Dyskinesia pipeline therapies in various stages of development include GOCOVRI, JM-010, NLX-112 (befiradol), and others.
Key benefits of the Parkinson's Disease Levodopa-Induced Dyskinesia market report:
Parkinson's Disease Levodopa-Induced Dyskinesia market report covers a descriptive overview and comprehensive insight of the Parkinson's Disease Levodopa-Induced Dyskinesia Epidemiology and Parkinson's Disease Levodopa-Induced Dyskinesia market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
The Parkinson's Disease Levodopa-Induced Dyskinesia market report provides insights on the current and emerging therapies.
Parkinson's Disease Levodopa-Induced Dyskinesia market report provides a global historical and forecasted market covering drug outreach in 7MM.
The Parkinson's Disease Levodopa-Induced Dyskinesia market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Parkinson's Disease Levodopa-Induced Dyskinesia market.

Got queries? Click here to know more about the Parkinson's Disease Levodopa-Induced Dyskinesia Market Landscape https://www.delveinsight.com/sample-request/parkinsons-disease-levodopa-induced-dyskinesia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Parkinson's Disease Levodopa-Induced Dyskinesia Overview

Parkinson's disease (PD) is a serious and progressively worsening neurodegenerative disorder primarily marked by significant motor dysfunctions such as slowness of movement (bradykinesia), tremors, and muscle stiffness (rigidity). In addition to these physical symptoms, PD is also associated with cognitive decline, psychiatric issues, and complications like levodopa-induced dyskinesia (LID) due to long-term treatment.

Levodopa (L-DOPA) remains the most effective medication for managing PD symptoms, but extended use often leads to involuntary movements, known as dyskinesias. These may start as mild but can progress to severely disabling motor complications, significantly affecting a patient's quality of life. Statistics indicate that over 50% of PD patients experience LID after five years of continuous levodopa therapy.

LID presents with diverse clinical manifestations, most commonly resembling chorea or choreoathetosis. Other presentations include myoclonus, ballism, and akathisia-a condition characterized by extreme motor restlessness. Less common forms involve symptoms like a high-stepping, exaggerated gait, rapid alternating leg movements (RAMs), eyelid spasms (blepharospasm), and various mixed abnormal movement patterns.

Parkinson's Disease Levodopa-Induced Dyskinesia Market Outlook

Therapeutic options for managing Parkinson's disease Levodopa-induced Dyskinesia include non-pharmacological treatments such as bandage contact lenses, topical ocular cycloplegic agents, topical ocular NSAIDs, and oral medications. For acute pain management, oral medications are typically categorized into non-opioid and opioid medications. Non-opioid options include prescription or over-the-counter NSAIDs and acetaminophen. Pain resulting from surgery, injury, infection, or inflammation at the front of the eye is usually treated with topical steroids, topical NSAIDs, systemic NSAIDs, lubricant ointments, gels or drops, bandage contact lenses, or occasional doses of oral opiates or topical anesthetics.

The US FDA approved GOCOVRI (amantadine) extended-release capsules in 2017 as the first medication for treating PD patients on levodopa-based therapy. In 2021, the FDA also approved GOCOVRI extended-release tablets as an adjunctive treatment for levodopa/carbidopa patients with PD experiencing off episodes. While several drugs have been approved for treating PD patients, GOCOVRI remains the only drug approved specifically for Parkinson's disease Levodopa-induced Dyskinesia. Nevertheless, pharmaceutical companies are continuously working to develop new therapies to address the needs of PD patients with Levodopa-induced Dyskinesia. Moreover, factors such as advancements in treatment options, the increasing prevalence of Parkinson's disease, evolving regulatory frameworks, and growing awareness among healthcare providers and patients are expected to shape the market dynamics for Parkinson's disease Levodopa-induced Dyskinesia.

Discover how the parkinson's disease levodopa-induced dyskinesia market is rising in the upcoming years @ https://www.delveinsight.com/report-store/parkinsons-disease-levodopa-induced-dyskinesia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Parkinson's Disease Levodopa-Induced Dyskinesia Marketed Drugs and Key Companies
GOCOVRI: Supernus Pharmaceuticals

Parkinson's Disease Levodopa-Induced Dyskinesia Emerging Drugs and Key Companies

JM-010: Bukwang Pharmaceutical/Contera Pharma
NLX-112 (befiradol): Neurolixis SAS/Gala laboratories

To know which therapies are driving the parkinson's disease levodopa-induced dyskinesia market, visit: https://www.delveinsight.com/sample-request/parkinsons-disease-levodopa-induced-dyskinesia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Scope of the Parkinson's Disease Levodopa-Induced Dyskinesia Market Report

Study Period: 2020-2034
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Parkinson's Disease Levodopa-Induced Dyskinesia Companies: PharmaTher Inc., Neurolixis SAS, Gala laboratories, Bukwang Pharmaceutical, Contera Pharma, Vistagen, Ipsen Pharma, Newron Pharmaceuticals, Zambon Pharmaceuticals, Celon Pharma SA, and others
Key Parkinson's Disease Levodopa-Induced Dyskinesia Therapies: IGOCOVRI, JM-010, NLX-112 (befiradol), and others
Parkinson's Disease Levodopa-Induced Dyskinesia Therapeutic Assessment: Parkinson's Disease Levodopa-Induced Dyskinesia current marketed and Parkinson's Disease Levodopa-Induced Dyskinesia emerging therapies
Parkinson's Disease Levodopa-Induced Dyskinesia Market Dynamics: Parkinson's Disease Levodopa-Induced Dyskinesia market drivers and Parkinson's Disease Levodopa-Induced Dyskinesia market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
Parkinson's Disease Levodopa-Induced Dyskinesia Unmet Needs, KOL's views, Analyst's views, Parkinson's Disease Levodopa-Induced Dyskinesia Market Access and Reimbursement

Table of Contents

1. Report Introduction
2. Executive Summary
3. SWOT analysis
4. Parkinson's Disease Levodopa-Induced Dyskinesia Patient Share (%) Overview at a Glance
5. Parkinson's Disease Levodopa-Induced Dyskinesia Market Overview at a Glance
6. Parkinson's Disease Levodopa-Induced Dyskinesia Disease Background and Overview
7. Parkinson's Disease Levodopa-Induced Dyskinesia Epidemiology and Patient Population
8. Country-Specific Patient Population of Parkinson's Disease Levodopa-Induced Dyskinesia
9. Parkinson's Disease Levodopa-Induced Dyskinesia Current Treatment and Medical Practices
10. Unmet Needs
11. Parkinson's Disease Levodopa-Induced Dyskinesia Emerging Therapies
12. Parkinson's Disease Levodopa-Induced Dyskinesia Market Outlook
13. Country-Wise Parkinson's Disease Levodopa-Induced Dyskinesia Market Analysis (2020-2034)
14. Market Access and Reimbursement of Therapies
15. Market drivers
16. Market barriers
17. Appendix
18. Parkinson's Disease Levodopa-Induced Dyskinesia Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Click here to read more about Parkinson's Disease Levodopa-Induced Dyskinesia Market Outlook 2034 https://www.delveinsight.com/report-store/parkinsons-disease-levodopa-induced-dyskinesia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Related Reports:

Parkinson's Disease Levodopa-Induced Dyskinesia Pipeline Insights, DelveInsight

"Parkinson's Disease Levodopa-Induced Dyskinesia Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Parkinson's Disease Levodopa-Induced Dyskinesia market. A detailed picture of the Parkinson's Disease Levodopa-Induced Dyskinesia pipeline landscape is provided, which includes the disease overview and Parkinson's Disease Levodopa-Induced Dyskinesia treatment guidelines.

Contact Info:

Kritika Rehani, Team Leader Marketing & Branding
krehani@delveinsight.com
info@delveinsight.com
www.delveinsight.com
+14699457679

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.